Kliiniliste Uuringute Keskus OÜ
- Address
- lock Available on a paid plan
Kliiniliste Uuringute Keskus OÜ - Rheumatology and Immunology Research Center
Kliiniliste Uuringute Keskus OÜ is a specialized clinical research center with extensive expertise in rheumatological conditions and immunological disorders. The center demonstrates particular strength in conducting Phase 3 pivotal trials and long-term extension studies for chronic inflammatory diseases, evaluating both novel therapeutics and biosimilar products in accordance with international regulatory standards.
- Rheumatic diseases including psoriatic arthritis, axial spondyloarthritis, and rheumatoid arthritis with focus on biologic therapies and JAK inhibitors
- Dermatological and immunological conditions, particularly moderate-to-severe atopic dermatitis and chronic inflammatory skin disorders
- Bone metabolism disorders and post-menopausal osteoporosis research with bone mineral density assessments
- Vaccine immunogenicity studies and infectious disease prevention in adult and elderly populations
The center's research portfolio encompasses comprehensive efficacy and safety evaluations utilizing advanced clinical assessment tools such as DAS28-ESR, EASI scores, and ACR response criteria. With capabilities ranging from pharmacokinetic and pharmacodynamic analysis to immunogenicity monitoring, Kliiniliste Uuringute Keskus OÜ provides thorough investigation of both established and emerging therapeutic modalities, including monoclonal antibodies, biosimilars, and targeted synthetic disease-modifying antirheumatic drugs for complex autoimmune and inflammatory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 75 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 73 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1GlaxoSmithKline Biologicals2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GlaxoSmithKline Biologicals4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kliiniliste Uuringute Keskus OÜ
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis | Alfasigma S.p.A. | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 75 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) | 3 | Unknown | 2023-11-03 | 2025-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.